WH
CRSP icon

William Harnisch’s CRISPR Therapeutics CRSP Stock Holding History

William Harnisch’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$1.68M – 43
2021
Q3 		$1.68M Buy
+15,000
New +$1.88M 0.15% 18
2020
Q2 		– Sell
-21,821
Closed -$925K – 62
2020
Q1 		$925K Sell
21,821
-57,704
-73% -$2.98M 0.36% 14
2019
Q4 		$4.84M Sell
79,525
-60,000
-43% -$3.28M 0.99% 17
2019
Q3 		$5.72M Buy
+139,525
New +$6.67M 1.33% 12

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

William Harnisch's CRSP Position: Q4 2021 in Review

William Harnisch sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 15,000 shares — an estimated $1.68M sold.

William Harnisch first reported a position in CRSP in Q3 2019 and held it in 4 quarters. The position peaked at $5.72M in Q3 2019. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • William Harnisch reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • William Harnisch sold 15,000 CRISPR Therapeutics shares in Q4 2021, an estimated $1.68M.
  • William Harnisch first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 4 quarters.
  • William Harnisch's CRISPR Therapeutics position peaked at $5.72M in Q3 2019.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Peconic Partners's 13F filing for Q4 2021, filed 14 Feb 2022.